Arcturus Therapeutics: Strong Analyst Recommendations, Price Target Above Current Share PriceArcturus Therapeutics: Strong Analyst Recommendations, Price Target Above Current Share Price Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has received favorable recommendations from analysts, with an average “Buy” rating from seven research firms. The consensus 12-month price target is $64.86, significantly higher than the current share price of $21.48. Recent Analyst Reports * William Blair: Reiterated an “Outperform” rating * HC Wainwright: Retained a “Buy” rating with a price target of $60.00 * Canaccord Genuity Group: Lowered price target to $86.00 but maintained a “Buy” rating Share Performance and Financials Shares of ARCT have declined by 9.2%. The company’s moving averages and price-to-earnings ratios indicate a potential for undervaluation. In its latest quarterly results, Arcturus Therapeutics reported a net loss per share of ($1.00), but revenue exceeded analyst expectations. Insider Trading and Institutional Ownership COO Pad Chivukula recently sold 26,000 shares of ARCT stock, while several hedge funds and institutional investors have increased their holdings in the company. Institutional investors currently hold a substantial 94.54% of ARCT’s shares. About Arcturus Therapeutics Arcturus Therapeutics is a clinical-stage company developing mRNA therapeutics and vaccines for infectious diseases, rare liver diseases, and respiratory diseases. It utilizes LUNAR lipid-mediated delivery and STARR mRNA technology platforms. Conclusion Arcturus Therapeutics has received strong analyst recommendations and a high price target. While the stock has experienced a recent decline, its financial performance and insider trading suggest potential for future appreciation. Institutional investors’ confidence in the company is a positive sign. Investors may consider monitoring ARCT’s progress as it advances its clinical trials and brings products to market.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has an average recommendation of “Buy” from the seven research firms currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a “Buy” rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the past year is $64.86.
ARCT has been the subject of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday. Finally, Canaccord Genuity Group lowered their price target on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, May 10th.
View our latest research report on Arcturus Therapeutics
Arcturus Therapeutics shares drop 9.2%
Shares of NASDAQ ARCT opened at $21.48 on Wednesday. The company’s 50-day moving average is $29.99 and its 200-day moving average is $32.57. The stock has a market cap of $578.46 million, a price-to-earnings ratio of -5.49 and a beta of 2.65. Arcturus Therapeutics has a 12-month low of $17.52 and a 12-month high of $45.00.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly results on Wednesday, May 8. The biotechnology company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.17. The company had revenue of $38.01 million for the quarter, compared to analysts’ expectations of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. On average, research analysts expect Arcturus Therapeutics to post -4.39 EPS for the current fiscal year.
Insider Buying and Selling at Arcturus Therapeutics
In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total value of $1,040,260.00. Following the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at approximately $17,902,394.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed at this link. Company insiders own 13.80% of the company’s stock.
Institutional investors weigh in on Arcturus Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 7.7% in the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock worth $64,564,000 after purchasing an additional 146,141 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Arcturus Therapeutics by 11.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock worth $34,336,000 after purchasing an additional 115,087 shares in the last quarter. FMR LLC increased its stake in shares of Arcturus Therapeutics by 8.6% in the 3rd quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock worth $24,024,000 after purchasing an additional 74,081 shares in the last quarter. Granahan Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 12.9% in the 4th quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock worth $14,200,000 after purchasing an additional 51,504 shares in the last quarter. Finally, Great Lakes Advisors LLC acquired a new position in shares of Arcturus Therapeutics in the 4th quarter worth approximately $6,531,000. 94.54% of the shares are currently held by institutional investors and hedge funds.
About Arcturus Therapeutics
(Get Free Report
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA therapeutics and vaccine company, is focused on the development of infectious disease vaccines and other products in rare liver and respiratory diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
read more
Get daily news and reviews for Arcturus Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Arcturus Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
